Forging ahead on dental front

One way for the biotech industry to win back the hearts of investors would be to come up with something everybody wants, like a cheaper and less painful way of going to the dentist. While most potentially large markets are glutted with companies vying to develop products, the dental area remains virtually untapped.

Creative BioMolecules Inc., which has the field virtually to itself, said last week that it is initiating clinical trials of its OP-1 human osteogenic protein for dentin regeneration.